Cover Image
市場調查報告書

Liraglutide的中國市場

Investigation Report on China Liraglutide Market, 2011-2019

出版商 China Research and Intelligence 商品編碼 332762
出版日期 內容資訊 英文 25 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Liraglutide的中國市場 Investigation Report on China Liraglutide Market, 2011-2019
出版日期: 2015年06月11日 內容資訊: 英文 25 Pages
簡介

Liraglutide是2008年NovoNordisk開發的糖尿病治療藥GLP-1類同物,2013年寫下全球市場20億美元以上的銷售量記錄。Liraglutide在2011年10月打入中國市場以來其銷售量急速擴大,2011年不到50萬人民幣的銷售量到2014年已達1971萬人民幣的規模。

本報告提供中國的Liraglutide市場規模與今後預測,提供您主要製藥公司及劑型別市場佔有率,銷售價格等資訊。

第1章 Liraglutide的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國Liraglutide的市場簡介

  • Liraglutide的專利及核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國Liraglutide銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國Liraglutide的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國Liraglutide的劑型的相關調查

  • 劑型別市場佔有率:以銷售額為準
  • 劑型別市場佔有率:以銷售量為準

第6章 中國醫院的Liraglutide的標準價格

第7章 中國市場中Liraglutide的主要製藥公司

第8章 中國Liraglutide的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1506202

As economy develops and living standards improve, Chinese people's dietary pattern changes, resulting in excess heat. Meanwhile, the drop in physical activities leads to the increased obesity rate. Other factors like the ageing population also play a role in the rapid increase of diabetes incidence in China.

Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, was developed by Novo Nordisk in 2008 to treat diabetes. Liraglutide, a derivative attained by attaching a fatty acid molecule to GLP-1 molecule, can reduce the HbA1c level and weight of type 2 diabetes mellitus (T2DM) patients and improve the function of beta cells. Since it stimulates insulin secretion and inhibits glucagon secretion only when blood glucose levels are higher than normal, it shows negligible risk of hypoglycemia. On Jan. 25, 2010, liraglutide was approved by FDA to be used as the second-line drug alone or together with other oral antidiabetic drugs for the treatment of T2DM. In 2013, the sales value of liraglutide around the world exceeded USD 2 billion.

After entering China in Oct. 2011, liraglutide develops fast with annual sales value rising from less than CNY 0.5 million in 2011 to CNY 19.71 million in 2014 and CAGR reaching up to 246% during the period of 2011-2013. Currently, liraglutide market in China is monopolized by Novo Nordisk. Although liraglutide, as an imported drug, is priced relatively high in China, it still has good market prospects.

Readers can get at least the following information from this report:

  • market size of liraglutide in China
  • price of liraglutide in Chinese market
  • share of dosage forms of liraglutide in China
  • market outlook of liraglutide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Liraglutide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Liraglutide in China

  • 2.1. Patent and Approval Status of Liraglutide in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Liraglutide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Liraglutide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Liraglutide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Liraglutide in Chinese Hospitals in 2014

7. Major Manufacturers of Liraglutide in Chinese Market, 2010-2014

8. Market Outlook of Liraglutide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Liraglutide in China
  • Chart Sales Status of Liraglutide in China, 2011-2014
  • Chart Sales Value of Liraglutide in China, 2011-2014
  • Chart Sales Value of Liraglutide in Some Regions in China, 2011-2014
  • Chart Sales Volume of Liraglutide in China, 2011-2014
  • Chart Sales Volume of Liraglutide in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Liraglutide Made by Novo Nordisk (Denmark) in China, 2011-2014
  • Chart Price of Liraglutide Made by Novo Nordisk in Some Chinese Cities in 2014
Back to Top